Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Executive Vice President | October 31, 2019 | November 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date October 31, 2019 · Filed November 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,286 |
Reported balance
After 2019-10-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-10-31 · Grant · Acquired 39,286 · Balance 39,286 F1: Represents a deferred stock award of 39,286 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in equal installments on October 31, 2020, 2021 and 2022, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from October 31, 2019 to the earlier of (i) October 31, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date, or with respect to a change of control, the per share purchase price in the change of control). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F2: Includes the award described in footnote (1) above. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2029-10-31 | Direct | 86,614 |
Reported balance
After 2019-10-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-31 · Grant · Acquired 86,614 · Balance 86,614 F3: The options vest in four equal installments on October 31, 2020, 2021, 2022 and 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a deferred stock award of 39,286 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in equal installments on October 31, 2020, 2021 and 2022, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from October 31, 2019 to the earlier of (i) October 31, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date, or with respect to a change of control, the per share purchase price in the change of control). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported.
F2: Includes the award described in footnote (1) above.
F3: The options vest in four equal installments on October 31, 2020, 2021, 2022 and 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2019 Filed Nov 5, 2019 23:03 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantStock option (right to buy) · Derivative | 86,614 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001209191-19-055318 · doc4.xml · derivative · entry 2 Singh Yash · CIK 0001793157 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,614 Underlying: Common Stock, par value $0.01 per share · 86,614 shares Expires 2029-10-31 F3 · derivative.exercise_date: The options vest in four equal installments on October 31, 2020, 2021, 2022 and 2023. Read SEC document |
| October 31, 2019 Filed Nov 5, 2019 23:03 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 39,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055318 · doc4.xml · nonDerivative · entry 1 Singh Yash · CIK 0001793157 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,286 F1 · shares: Represents a deferred stock award of 39,286 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in equal installments on October 31, 2020, 2021 and 2022, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from October 31, 2019 to the earlier of (i) October 31, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date, or with respect to a change of control, the per share purchase price in the change of control). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F2 · balance_after: Includes the award described in footnote (1) above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.